INIS Details Executive Equity Compensation for 2024

TL;DR

**INIS's executive compensation is heavily tied to equity, signaling a long-term focus but lacking immediate financial performance details.**

AI Summary

INTERNATIONAL ISOTOPES INC (INIS) filed a DEF 14A on May 27, 2025, detailing executive compensation for the fiscal year ended December 31, 2024. The filing primarily focuses on equity award valuations for both Named Executive Officers (PEO) and other non-PEO executives. For PEOs, the inclusion of equity values for 2024 is highlighted, alongside changes in fair value of prior year equity awards vested in 2024 and the year-end fair value of outstanding and unvested equity awards granted in 2024. Similar detailed breakdowns are provided for non-PEO executives across 2022, 2023, and 2024, indicating a consistent approach to equity-based incentives. The document does not provide specific revenue or net income figures, nor does it outline key business changes or a strategic outlook, focusing instead on compensation disclosures. Risks related to compensation structures are implicitly present but not explicitly detailed with dollar amounts or percentages in this specific filing excerpt.

Why It Matters

This DEF 14A filing provides crucial transparency into how INTERNATIONAL ISOTOPES INC compensates its leadership, directly impacting investor confidence and governance assessments. Understanding the structure and value of equity awards for both Named Executive Officers and other key personnel helps investors evaluate management alignment with shareholder interests. In the competitive industrial instruments sector, attractive and performance-linked compensation packages are vital for retaining top talent, while excessive or poorly structured awards can signal potential governance issues and dilute shareholder value. This disclosure allows for benchmarking against competitors and assessing the company's commitment to long-term value creation.

Risk Assessment

Risk Level: medium — The filing details equity compensation without providing corresponding financial performance metrics like revenue or net income, making it difficult to assess if compensation is aligned with company performance. The lack of specific dollar values for these equity awards in the provided excerpt also limits a comprehensive risk assessment, as excessive equity grants could lead to dilution.

Analyst Insight

Investors should scrutinize the full DEF 14A to find the specific dollar values of equity awards and cross-reference them with INIS's recent 10-K or 10-Q filings for revenue and net income figures. This will allow for a proper assessment of executive compensation alignment with company performance and shareholder value.

Financial Highlights

debt To Equity

Not Disclosed

revenue

Not Disclosed

operating Margin

Not Disclosed

total Assets

Not Disclosed

total Debt

Not Disclosed

net Income

Not Disclosed

eps

Not Disclosed

gross Margin

Not Disclosed

cash Position

Not Disclosed

revenue Growth

Not Disclosed

Executive Compensation

Key Numbers

• 2024 — Fiscal Year (Period for which executive compensation data is primarily disclosed)
• 2025-05-27 — Filing Date (Date the DEF 14A was filed with the SEC)
• 1231 — Fiscal Year End (INTERNATIONAL ISOTOPES INC's fiscal year ends on December 31st)

Key Players & Entities

• INTERNATIONAL ISOTOPES INC (company) — Filer of DEF 14A
• SEC (regulator) — Recipient of DEF 14A filing
• Idaho Falls (location) — Business address city for INIS
• TX (location) — State of incorporation for INIS
• 2025-05-27 (date) — Filing date of DEF 14A
• 2024-12-31 (date) — Fiscal year end for compensation data
• 000-22923 (regulatory) — SEC File Number for INIS
• 208-524-5300 (contact) — Business phone number for INIS

FAQ

Industry Context

INTERNATIONAL ISOTOPES INC operates in the industrial instruments sector, specifically focusing on the production and distribution of isotopes. This niche market is characterized by specialized applications in medical, industrial, and research fields. The industry requires significant expertise in handling radioactive materials and adherence to stringent regulatory standards.

Regulatory Implications

As a producer of isotopes, INTERNATIONAL ISOTOPES INC is subject to extensive regulatory oversight from bodies like the Nuclear Regulatory Commission (NRC) and potentially international agencies. Compliance with safety, security, and environmental regulations is paramount and can impact operational costs and business continuity.

What Investors Should Do

1. Review executive compensation details for alignment with company performance.
2. Monitor regulatory compliance and any potential impacts on operations.

Key Dates

• 2024-12-31: Fiscal Year End — Marks the end of the reporting period for which executive compensation data is primarily disclosed.
• 2025-05-27: DEF 14A Filing Date — The date INTERNATIONAL ISOTOPES INC filed its Definitive Proxy Statement with the SEC, providing details on executive compensation and corporate governance.

Glossary

DEF 14A

A Definitive Proxy Statement filed with the SEC by public companies. It contains detailed information about matters to be voted on at shareholder meetings, including executive compensation, director elections, and other corporate governance issues. (This filing provides the primary source of information regarding INTERNATIONAL ISOTOPES INC's executive compensation practices for the fiscal year 2024.)

PEO

Principal Executive Officer. This typically refers to the highest-ranking executive in a company, such as the Chief Executive Officer (CEO). (The filing distinguishes compensation details for the PEO from other executives, highlighting their specific compensation structure.)

Equity Awards

Forms of compensation granted to employees that are tied to the value of the company's stock. This can include stock options, restricted stock units (RSUs), or performance shares. (The DEF 14A extensively details the valuation and changes in fair value of equity awards granted to executives, indicating their importance in the compensation strategy.)

Fair Value

The estimated price at which an asset would change hands between a willing buyer and a willing seller, neither being under any compulsion to buy or to sell and both having reasonable knowledge of relevant facts. (The filing uses fair value to assess the worth of equity awards granted to executives, both at the time of grant and as their value changes over time.)

Year-Over-Year Comparison

This DEF 14A filing for the fiscal year 2024 focuses heavily on the valuation of equity awards for both PEO and non-PEO executives, detailing grants, vesting, and changes in fair value across 2022, 2023, and 2024. Unlike a typical annual report, it does not provide comparative financial metrics such as revenue or net income growth. The emphasis is solely on compensation disclosure, making a direct comparison of financial performance metrics to a prior filing impossible based on this document alone.

Filing Details

This Form DEF 14A (Form DEF 14A) was filed with the SEC on May 27, 2025 regarding INTERNATIONAL ISOTOPES INC (INIS).

View full filing on EDGAR

View Full Filing

View this DEF 14A filing on SEC EDGAR